Company intelligence
Amprion
The Leader in Alpha-Synuclein SAA Diagnostics for Neurodegenerative Disorders
Biotechnology
San Francisco, US
37 employees
Founded 2007
2 public signals
About Amprion
Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing. Amprion’s SAAmplify™-ɑSYN (formerly SYNTap®) Biomarker Test is a first-in-class, qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies (by detecting pathogenic ɑ-synuclein) such as Parkinson’s disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer’s disease (AD) with Lewy body variant.
Verified activity
Signals from Amprion
2 published signals
Research & Knowledge
Amprion shared lessons learned evaluating novel neurodegenerative biomarkers and diagnostics across cognitive and motor disease progression with the editorial team at Drug Development News.
Reported by Amprion
Research & Knowledge
Amprion CEO and Co-Founder Russ Lebovitz published an article in Drug Discovery News discussing the importance of multimodal approaches in neurodegenerative disease characterization, clinical trial design, and precision medicine.
Reported by Amprion